David M. Kurtz, MD, PhD
Circulating tumor DNA (ctDNA) has piqued the interest of researchers as an emerging method to detect and diagnose various malignancies, including lymphoma. David M. Kurtz, MD, PhD, said that this technology will be coming to the clinic soon, and may be as routinely used as a PET or CT scan is to detect disease.
“ctDNA is different,” said Kurtz. “This is something that we need to educate all providers about and decide how we are going to use this moving forward in our routine clinical paradigms.”
Utilizing liquid biopsies to collect ctDNA in conjunction with next-generation sequencing (NGS) is a method that is being used across multiple tumor types including breast cancer, non–small cell lung cancer, and sarcoma. In lymphoma specifically, ctDNA can be used to monitor the disease throughout therapy, including at relapse and at the completion of therapy, according to Kurtz.
... to read the full story